Medical Cannabis for Long COVID — Switzerland 2026
Long COVID has no established standard therapy. Cannabinoids target fatigue, brain fog and sleep — cheaper for members.
Long COVID / post-COVID syndrome affects an estimated 300,000 people in Switzerland. Neuroinflammation and dysautonomia are core mechanisms. CBD is anti-inflammatory and neuroprotective; THC micro-doses improve sleep, appetite and anxiety. 2022–2024 cohorts show 60–75 % symptom relief. CannabisClub members: 50 CHF flat instead of 190.
What the studies show
Nguyen 2022 (in vitro): CBD inhibits SARS-CoV-2 replication and reduces inflammatory cytokines.
Cohorts 2022–2024: 60–75 % of Long COVID patients report CBD/THC improvement in fatigue, sleep, anxiety.
Symptom-oriented use
Fatigue: CBD 25–50 mg twice daily — anti-inflammatory; avoid THC (may worsen fatigue).
Brain fog: CBD 25 mg twice daily + low-dose CBG (10–20 mg) for clarity.
Good to know
Cannabis is symptomatic, not curative.
Slow titration essential — Long COVID patients are often medication-sensitive (POTS, MCAS).
Save as a CannabisClub member
Post-COVID clinics charge 190–290 CHF for cannabis consult. Members: 50 CHF flat, telemedicine possible. Registration free.
FAQ
Does cannabis cure Long COVID?
No. It eases symptoms (fatigue, sleep, pain, anxiety) and enables better participation in rehabilitation.
What does membership save?
50 CHF instead of 190 CHF per consultation. Registration free.
Does insurance cover it?
In documented post-COVID with fatigue/pain, increasingly possible via art. 71a — we check.
Cannabis for Long COVID — Prescription Switzerland 2026 (Members 50 CHF)